Vanguard Group Inc. Purchases 72,817 Shares of Celldex Therapeutics, Inc. $CLDX

Vanguard Group Inc. lifted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 1.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,027,407 shares of the biopharmaceutical company’s stock after buying an additional 72,817 shares during the quarter. Vanguard Group Inc. owned about 6.06% of Celldex Therapeutics worth $109,384,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in CLDX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Celldex Therapeutics by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after purchasing an additional 680 shares during the period. Millennium Management LLC increased its stake in shares of Celldex Therapeutics by 327.3% in the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock valued at $7,259,000 after acquiring an additional 306,330 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Celldex Therapeutics by 12.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock valued at $2,383,000 after acquiring an additional 14,979 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 501 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new stake in shares of Celldex Therapeutics in the 2nd quarter valued at about $347,000.

Analyst Ratings Changes

Several equities analysts recently issued reports on CLDX shares. The Goldman Sachs Group boosted their price objective on Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a research report on Monday, March 2nd. Wall Street Zen upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Monday, April 20th. Wolfe Research upgraded Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price objective for the company in a research report on Monday, March 23rd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.00.

Celldex Therapeutics Stock Down 0.9%

Shares of Celldex Therapeutics stock opened at $32.00 on Wednesday. Celldex Therapeutics, Inc. has a 12-month low of $18.47 and a 12-month high of $35.79. The stock has a market cap of $2.51 billion, a P/E ratio of -7.51 and a beta of 0.98. The business’s 50 day moving average is $31.82 and its 200-day moving average is $27.98.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.80 million. On average, sell-side analysts expect that Celldex Therapeutics, Inc. will post -4.53 EPS for the current year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.